| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | PLX4720 | CCLE | pan-cancer | AAC | -0.082 | 0.05 |
| mRNA | AEW541 | CCLE | pan-cancer | AAC | 0.086 | 0.06 |
| mRNA | navitoclax:sorafenib (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.066 | 0.06 |
| mRNA | PFI-1 | GDSC1000 | pan-cancer | AAC | 0.061 | 0.06 |
| mRNA | KHS101 | CTRPv2 | pan-cancer | AAC | -0.07 | 0.06 |
| mRNA | dabrafenib | GDSC1000 | pan-cancer | AAC | -0.055 | 0.06 |
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | -0.085 | 0.06 |
| mRNA | BMS-345541 | GDSC1000 | pan-cancer | AAC | 0.057 | 0.06 |
| mRNA | DMOG | GDSC1000 | pan-cancer | AAC | 0.059 | 0.06 |
| mRNA | tivantinib | CTRPv2 | pan-cancer | AAC | 0.082 | 0.06 |